Table 1.
The characteristics of all patients before PSM
| ALL | ICI + RT | CT + RT | P value | |
|---|---|---|---|---|
| N = 161 | N = 100 | N = 61 | ||
| Age (IQR) | 60 (54–66) | 60 (65–70) | 61(53-67.5) | 0.920 |
| Gender | 0.919 | |||
| Female | 31 (19.3%) | 20 (20.0%) | 11 (18.0%) | |
| Male | 130 (80.7%) | 80 (80.0%) | 50 (82.0%) | |
| PS score | 1.000 | |||
| 1 | 136 (84.5%) | 84 (84.0%) | 52 (85.2%) | |
| 2 | 25 (15.5%) | 16 (16.0%) | 9 (14.8%) | |
| Smoking history | 0.019 | |||
| None | 73 (45.3%) | 53 (53.0%) | 20 (32.8%) | |
| Yes | 88 (54.7%) | 47 (47.0%) | 41 (67.2%) | |
| Primary lesion | 0.026 | |||
| Left lung | 73 (45.3%) | 38 (38.0%) | 35 (57.4%) | |
| Right lung | 88 (54.7%) | 62 (62.0%) | 26 (42.6%) | |
| Surgery of lung | 0.464 | |||
| None | 120 (74.5%) | 77 (77.0%) | 43 (70.5%) | |
| Yes | 41 (25.5%) | 23 (23.0%) | 18 (29.5%) | |
| T stage | 0.653 | |||
| 1 | 22 (13.7%) | 16 (16.0%) | 6 (9.8%) | |
| 2 | 43 (26.7%) | 27 (27.0%) | 16 (26.2%) | |
| 3 | 35 (21.7%) | 20 (20.0%) | 15 (24.6%) | |
| 4 | 56 (34.8%) | 35 (35.0%) | 21 (34.4%) | |
| Unknown | 5 (3.1%) | 2 (2.0%) | 3 (4.9%) | |
| N stage | 0.409 | |||
| 0 | 44 (27.3%) | 25 (25.0%) | 19 (31.1%) | |
| 1 | 11 (6.8%) | 7 (7.0%) | 4 (6.6%) | |
| 2 | 59 (36.6%) | 34 (34.0%) | 25 (41.0%) | |
| 3 | 45 (28.0%) | 33 (33.0%) | 12 (19.7%) | |
| Unknown | 2 (1.2%) | 1 (1.0%) | 1 (1.6%) | |
| Extracranial metastases | 0.395 | |||
| None | 90 (55.9%) | 59 (59.0%) | 31 (50.8%) | |
| Yes | 71 (44.1%) | 41 (41.0%) | 30 (49.2%) | |
| Driver gene | 0.018 | |||
| None | 94 (58.4%) | 54 (54.0%) | 40 (65.6%) | |
| Yes | 28 (17.4%) | 24 (24.0%) | 4 (6.6%) | |
| Unknown | 39 (24.2%) | 22 (22.0%) | 17 (27.9%) | |
| Pathological type | 0.424 | |||
| Adenocarcinoma | 120 (74.5%) | 76 (76.0%) | 44 (72.1%) | |
| Squamous carcinoma | 26 (16.1%) | 17 (17.0%) | 9 (14.8%) | |
| NSCLC(NOS) | 15 (9.3%) | 7 (7.0%) | 8 (13.1%) | |
| Symptoms of BM | 1.000 | |||
| None | 100 (62.1%) | 62 (62.0%) | 38 (62.3%) | |
| Yes | 61 (37.9%) | 38 (38.0%) | 23 (37.7%) | |
| Type of brain radiotherapy | 0.024 | |||
| WBRT | 86 (53.4%) | 46 (46.0%) | 40 (65.6%) | |
| SRS | 75 (46.6%) | 54 (54.0%) | 21 (34.4%) | |
| Sequence of treatment | 0.576 | |||
| Upfront RT | 17(10.6%) | 9(9.0%) | 8(13.1%) | |
| Upfront ICI/CT | 144(89.4%) | 91(91.0%) | 53(86.9%) | |
| Number of BM | 0.857 | |||
| 1 | 70 (43.5%) | 45 (45.0%) | 25 (41.0%) | |
| 2 | 24 (14.9%) | 15 (15.0%) | 9 (14.8%) | |
| >=3 | 67 (41.6%) | 40 (40.0%) | 27 (44.3%) | |
| Size of BM | 0.001 | |||
| < 10 | 37 (23.0%) | 28 (28.0%) | 9 (14.8%) | |
| >=10, < 20 | 57 (35.4%) | 37 (37.0%) | 20 (32.8%) | |
| >=20, < 30 | 29 (18.0%) | 21 (21.0%) | 8 (13.1%) | |
| >=30 | 25 (15.5%) | 12 (12.0%) | 13 (21.3%) | |
| Unknown | 13 (8.1%) | 2 (2.0%) | 11 (18.0%) |
BM, brain metastasis; CT, chemotherapy; ICI, immune checkpoint inhibitor; NSCLC, non-small Cell Lung Cancer; NOS, not otherwise specified; PSM, propensity score matching; RT, radiotherapy; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy